Antibodies against CaSR peptides 41–74, 110–130, and 169–198 were significantly more prevalent in the APS1 patient group compared with controls (P < .0001, P = .0072 and P = .0216, respectively; see Table 3). This evidence concerns the gene CASR and Autoimmune polyendocrinopathy type 1.